• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    11/19/21 10:59:00 AM ET
    $AIH
    $AZN
    $BLCT
    $BTCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

    NEW YORK, Nov. 19, 2021 /CNW/ - Deutsche Bank today announced that the presentations from the November 16th and 17th  Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in Australia, China, Germany, France and the UK presented their equity stories and answered audience questions. The presentations are targeted to all types of investors as well as analysts interested in non-US companies.

    To log in, please use the following link: www.adr.db.com/dbvic 

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    The following companies participated in the conference:

    • Hywin ((HYW)
    • First Pacific ((Hong Kong: 142_HK, OTC:FPAFY)
    • Telstra ((Australia: TLS, OTC:TLSYY)
    • BlueCity Holdings ((BLCT)
    • Yiren Digital ((YRD)
    • Ecofibre ((Australia: EOF, OTC:EOFBY)
    • Ipsen ((Paris: IPN, OTC:IPSEY)
    • Travis Perkins ((London: TPK, OTC:TPRKY)
    • HUTCHMED ((HCM, London: HCM))
    • China Online Education ((COE)
    • NIO ((NIO)
    • Aesthetic Medical International Holdings ((AIH)
    • Quhuo ((QH)
    • AstraZeneca ((London: AZN, NASDAQ:AZN)
    • BIT Mining ((BTCM)
    • Hugo Boss ((Germany: BOSS, OTC:BOSSY)

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2021 Deutsche Bank AG. All rights reserved.

    SOURCE dbVIC - Deutsche Bank Depositary Receipts Virtual Investor Conference

    Cision View original content: http://www.newswire.ca/en/releases/archive/November2021/19/c6486.html

    Get the next $AIH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AIH
    $AZN
    $BLCT
    $BTCM

    CompanyDatePrice TargetRatingAnalyst
    NIO Inc.
    $NIO
    6/17/2025$3.70 → $3.80Sell → Neutral
    Goldman
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    NIO Inc.
    $NIO
    2/4/2025$4.70Overweight → Neutral
    Analyst
    NIO Inc.
    $NIO
    1/7/2025Buy → Hold
    HSBC Securities
    NIO Inc.
    $NIO
    11/25/2024$4.80 → $3.90Neutral → Sell
    Goldman
    More analyst ratings

    $AIH
    $AZN
    $BLCT
    $BTCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NIO upgraded by Goldman with a new price target

      Goldman upgraded NIO from Sell to Neutral and set a new price target of $3.80 from $3.70 previously

      6/17/25 8:09:40 AM ET
      $NIO
      Auto Manufacturing
      Consumer Discretionary
    • HUTCHMED downgraded by HSBC Securities

      HSBC Securities downgraded HUTCHMED from Buy to Hold

      5/13/25 3:20:36 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    SEC Filings

    See more
    • SEC Form 6-K filed by Yiren Digital Ltd.

      6-K - Yiren Digital Ltd. (0001631761) (Filer)

      7/24/25 4:01:08 PM ET
      $YRD
      Finance: Consumer Services
      Finance
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/24/25 1:09:49 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/22/25 6:33:10 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Yiren Digital Releases its 2024 ESG Report: AI Deepens Sustainable Practices Across the Board

      BEIJING, July 24, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia, today announced the release of its annual ESG report for the year ended December 31, 2024. The report highlights Yiren Digital's mission of "Better Lives Through Digital Innovation",  demonstrating the Company's unwavering dedication to environmental sustainability and social responsibility. Mr. Ning Tang, Chairman and CEO of Yiren Digital, commented that sustainable development has become a global consensus and a defining mission for enterprises. As a leading AI-driven fintech platform, t

      7/24/25 8:37:00 AM ET
      $YRD
      Finance: Consumer Services
      Finance
    • Yiren Digital to Release 2024 ESG Report on June 24, 2025

      BEIJING, July 22, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia, announced that it plans to release its annual ESG report for the year ended December 31, 2024, before U.S. market opens on Thursday, June 24, 2025. Safe Harbor Statement This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology

      7/22/25 7:15:00 AM ET
      $YRD
      Finance: Consumer Services
      Finance
    • AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

      Investment will support AstraZeneca's ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company's largest single investment in a facility to date AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in A

      7/21/25 5:35:00 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Leadership Updates

    Live Leadership Updates

    See more
    • 51Talk Online Education Group to Present on the Emerging Growth Conference on June 17, 2025.

      51Talk Online Education Group invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SINGAPORE, June 12, 2025 /PRNewswire/ -- 51Talk Online Education Group (the "Company") (NYSE:COE), a global online education platform with core expertise in English education, is pleased to announce that it has been invited to present on the Emerging Growth Conference on June 17, 2025. The next Emerging Growth Conference is presenting on June 17, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's inve

      6/12/25 5:30:00 AM ET
      $COE
      Other Consumer Services
      Real Estate
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme

      11/20/24 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Financials

    Live finance-specific insights

    See more
    • Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

      Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

      7/14/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yiren Digital Reports First Quarter 2025 Financial Results

      BEIJING, June 12, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia, today announced its unaudited financial results for the quarter ended March 31, 2025. First Quarter 2025 Operational Highlights Financial Services Business Total loans facilitated in the first quarter of 2025 reached RMB15.2 billion (US$2.1 billion), representing a slight decrease of 1% from RMB15.4 billion in the fourth quarter of 2024 and compared to RMB11.9 billion in the same period of 2024.Cumulative number of borrowers served reached 12,909,436 as of March 31, 2025, representing an

      6/12/25 5:30:00 AM ET
      $YRD
      Finance: Consumer Services
      Finance
    • 51Talk Online Education Group Announces First Quarter 2025 Results

      SINGAPORE, June 9, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the first quarter ended March 31, 2025. First Quarter 2025 Financial and Operating Highlights Gross billings[1] for the first quarter of 2025 were US$21.9 million, a 74.6% growth from the first quarter of 2024.Net revenues were US$18.2 million for the first quarter of 2025, a 93.1% increase from US$9.4 million for the first quarter of 2024.The number of active students with attended lesson consumption was approximately 81,100 in the first quarter of 2025, repres

      6/9/25 6:00:00 AM ET
      $COE
      Other Consumer Services
      Real Estate

    $AIH
    $AZN
    $BLCT
    $BTCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

      SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

      12/17/24 4:07:04 PM ET
      $COE
      Other Consumer Services
      Real Estate
    • SEC Form SC 13D filed by Quhuo Limited

      SC 13D - QUHUO Ltd (0001781193) (Subject)

      10/15/24 7:19:18 PM ET
      $QH
      Business Services
      Consumer Discretionary
    • SEC Form SC 13D filed by Quhuo Limited

      SC 13D - QUHUO Ltd (0001781193) (Subject)

      10/15/24 7:17:52 PM ET
      $QH
      Business Services
      Consumer Discretionary